Garvan Institute of Medical Research

What Garvan Institute of Medical Research does

Garvan Institute of Medical Research is an Australian nonprofit medical research institute founded in 1963 and headquartered in Darlinghurst, Sydney, operating from a single campus at 384 Victoria Street. The institute concentrates its research effort on three converging scientific domains — genomics, cancer, and immunology — and runs 43 labs and groups organized into five strategic programs (Cancer Plasticity and Dormancy, Cancer Ecosystems, Immune Biotherapies, Precision Immunology, and Translational Genomics). It serves patients across cancer, autoimmune, metabolic, rare disease, neurological, and skeletal disease indications through clinical trials, disease registries, and translational research, while also functioning as a training hub for over 100 PhD, Masters, and Honours students via a conjoint arrangement with UNSW Sydney.

The technology stack combines cutting-edge wet-lab platforms — Nanopore Sequencing for rapid genetic diagnosis (covering 50+ genetic diseases), 10x Genomics' Xenium spatial biology platform, intravital imaging at the ACRF INCITe Centre, single-cell RNA sequencing pipelines, and antibody engineering — with proprietary AI tooling including AAnet (cancer cell pattern detection), Talos (automated variant prioritization for rare disease), and AI-driven discovery in non-coding DNA. The institute has built substantial proprietary data assets through large cohort studies including the OneK1K immune mapping project (over 1.25 million cells from nearly 1,000 individuals), the TenK10K partnership with Illumina (mapping 50 million cells), and the ASTRA pan-cancer spatial atlas (2,000 tumor samples across 10 cancer types). Research output is high-volume: 410 publications in 2025 and 20 clinical trials launched or progressed in the same year, with 5,655+ total publications in its database.

Garvan's revenue model is structurally different from a commercial enterprise. Funding is derived from four streams: peer-reviewed government grants (NHMRC and the Medical Research Future Fund), philanthropic donations (tax appeals, monthly giving, major gifts, bequests), commercialization through the in-house Commercial Development and Innovation (CDI) team (IP licensing, contract research, spin-off investments, SAB fees), and corporate research partnerships (e.g., $27M Illumina TenK10K, AUD$3M Anthropic). Pricing is not applicable as the institute does not sell commercial products. Go-to-market is multi-pronged: event-driven dissemination (symposiums, public lectures), community-led patient engagement through registries and trials, and OEM-embedded IP licensing to industry. The institute is operationally embedded in the St Vincent's Sydney Health Innovation Precinct alongside UNSW, St Vincent's Hospitals, Victor Chang Cardiac Research Institute, and Australian BioResources.

Name

Garvan Institute of Medical Research

Legal name

Garvan Institute of Medical Research

Website

https://garvan.org.au

Company type

Private

Founded year

1963

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Garvan Institute of Medical Research is an Australian nonprofit medical research institute in Sydney, founded in 1963, conducting genomics, cancer, and immunology research across 43 labs and translating discoveries into clinical trials, diagnostic tools, and licensed therapeutics.

Ownership category

akta.pro rank

Product category

Medical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Biomedical research services
• Genomics and precision medicine
• Clinical trial services
• Cancer immunology research
• Translational medical research

Headquarters

HQ city

Darlinghurst

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Government Research Grants: Peer-reviewed government grants from agencies including NHMRC and the Medical Research Future Fund form a crucial part of funding for fundamental biomedical research.
2. Philanthropic Donations: Generous philanthropic investment from the community supports Garvan research. The institute runs donation campaigns including tax appeals and monthly giving programs.
3. Commercialization and Licensing: CDI team commercializes Garvan intellectual property through evaluation, licensing, collaborative R&D projects, contract research (fee for service), and investment into spin-off companies.
4. Consulting and Expert Opinion: Garvan researchers provide consulting work including expert opinion and Scientific Advisory Board (SAB) services to industry partners.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels11 records

Core offering

Garvan Institute of Medical Research is a nonprofit medical research organization that conducts fundamental and translational biomedical research across cancer, immunology, metabolic disease, rare disease, and neuroscience, delivered through five strategic research programs, six scientific platforms, two research centres, and a portfolio of clinical trials and patient registries. Outputs include peer-reviewed publications, trained research students via UNSW conjoint appointments, licensed intellectual property, and contract research services for industry partners through its Commercial Development and Innovation team.

Product overview

The Garvan Institute of Medical Research is a nonprofit research institution that operates as a platform of interconnected research services and programs rather than a commercial product company. Its offerings include five strategic research programs (Cancer Plasticity and Dormancy, Cancer Ecosystems, Immune Biotherapies, Precision Immunology, and Translational Genomics), two research centres (ACRF INCITe Centre and Centre for Population Genomics), six scientific platforms (Imaging, Data Science, Clinical Translation and Engagement, Genomics, Biologics, Development), and nine scientific services (animal imaging, animal research, clinical research facility, dynamic biomaterials analysis, genome editing, histopathology, microscopy, molecular genetics, and My Research results). The Institute also conducts multiple clinical trials and collaborative research programs including the ASTRA Consortium. Additionally, Garvan provides knowledge resources including the Medical Minds Podcast, Breakthrough Magazine, Science Explained content, and Art of Discovery visual exhibition.

Differentiator

Problem solved

Functional benefit

Brands

• ACRF INCITe Centre: Australian Cancer Research Foundation Intravital Imaging of Niches for Cancer Immune Therapy Centre - harnesses intravital imaging technology and immunotherapy to advance cancer treatment
• Centre for Population Genomics

Products and services

• Research Labs and Groups 43 research labs and groups investigating fundamental biomedical research questions across cancer, immunology, metabolism, and genomics. Each lab is led by a faculty lab or group leader who directs independent research programs.
• Strategic Research Programs Five strategic research programs organising Garvan's scientific effort: Cancer Plasticity and Dormancy, Cancer Ecosystems, Immune Biotherapies, Precision Immunology, and Translational Genomics.
• Research Centres Specialised research centres including the ACRF INCITe Centre (intravital imaging for cancer immune therapy) and the Centre for Population Genomics, each with their own directors and infrastructure.
• Scientific Platforms Shared technology platforms providing expertise in Imaging, Data Science, Clinical Translation and Engagement, Genomics, Biologics, and Development for use by researchers internally and externally.
• Scientific Services World-leading fee-for-service scientific capabilities including animal imaging, animal research, clinical research facility, dynamic biomaterials analysis, genome editing (MEGA), histopathology, microscopy, and molecular genetics.
• Clinical Trials Clinical studies including TIRTLE (tirzepatide), RESET1 (semaglutide), triple-negative breast cancer trial, Genomics of Rare Disease Registry, Australian Hearts Registry, Sudden Cardiac Arrest Registry, and GENIE newborn screening study.
• Research Collaborations Collaborative programs including AllClear (breast cancer relapse), CIRCA (immunogenomics), OCCAMS (multiple sclerosis), Australian Parkinson's Mission, Hope Research (autoimmune disease), Exceptional Responders Program, and Australian Pancreatic Cancer Alliance.
• ASTRA Consortium Asia-Pacific Spatial Translational Research Alliance led by Garvan Institute and University of Tokyo, using 10x Genomics' Xenium platform to build a pan-cancer spatial atlas mapping 2,000 tumor samples across ten major cancer types.
• Research Publications Database Public searchable database of Garvan Institute research publications with filtering by date range and search functionality, currently containing 5,655+ publications.

Quantifiable outcome

• 410 publications in 2025 including journal articles, reports, reviews, letters, books and book chapters
• +6 more outcomes

Named customers5 records

Segments9 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

17 partnerships are on record, tiered core and secondary.

• AnthropiccoreTechnology or Integration · 1 March 2026Anthropic signed a Memorandum of Understanding with the Australian government providing AUD$3 million in API credits to four Australian research institutions including Garvan. Garvan researchers will use Claude AI technology for disease diagnosis, genetic research, and workforce AI training. Partnership includes collaboration with Australia's AI Safety Institute and data center infrastructure exploration.
• University of TokyocoreStrategic or Co-development Partner · 1 November 2025ASTRA (Asia-Pacific Spatial Translational Research Alliance) consortium led by Garvan and University of Tokyo to create a pan-cancer spatial atlas using 10x Genomics' Xenium platform. Project will map 2,000 tumor samples across ten major cancer types to identify immune interactions and molecular features across Asia-Pacific populations underrepresented in global cancer data. Consortium launching November 2025 in Sydney.
• 10x GenomicscoreTechnology or Integration · 1 November 202510x Genomics providing spatial platform technology for ASTRA consortium pan-cancer spatial atlas project. The partnership establishes regional spatial biology hubs and digital infrastructure to advance precision oncology across the Asia-Pacific region.
• IlluminacoreStrategic or Co-development Partner · 1 January 2024$27 million TenK10K project partnership with Illumina, a global genomics and human health company, to help transform treatment of complex diseases starting with autoimmune diseases. Partnership aims to map 50 million human cells and uncover genetic fingerprints of disease.
• Amplia TherapeuticssecondaryStrategic or Co-development Partner · 1 January 2022Clinical trial collaboration testing Amplia's drug AMP945 which targets pancreatic tumor defenses (fibrous stroma) in patients with pancreatic ductal adenocarcinoma. Based on Garvan research findings.
• AllClearcoreStrategic or Co-development PartnerSolving one of the most urgent challenges in breast cancer – how to stop relapse. Collaborative program bringing together research expertise to address cancer dormancy and relapse.
• CIRCA (Clinical Immunogenomics Research Consortium Australasia)coreStrategic or Co-development PartnerCIRCA uses genomics to inform diagnosis and treatment for complex immunological diseases, bringing together researchers across Australasia to advance immunogenomics research.
• OCCAMSsecondaryStrategic or Co-development PartnerMultidisciplinary team investigating the link between Multiple Sclerosis (MS) and the Epstein-Barr virus, exploring new avenues for understanding and treating MS.
• Australian Parkinson's MissioncoreStrategic or Co-development PartnerFive-year, international collaborative program for Parkinson's disease integrating clinical trials with potentially transformative genomic analysis and biomarkers research.
• Hope ResearchcoreStrategic or Co-development PartnerRadical program to understand autoimmune disease. Researchers hypothesize there may be a common cause to type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
• Exceptional Responders ProgramsecondaryStrategic or Co-development PartnerCollaborative study of patients who have exceptional responses to cancer treatment, using this knowledge to help others with the disease through precision oncology approaches.
• Australian Pancreatic Cancer AlliancecoreStrategic or Co-development PartnerCollaborative network of organisations united by a shared mission to raise awareness of pancreatic cancer and accelerate meaningful progress for those affected by the disease.
• St Vincent's Sydney Health Innovation PrecinctcoreStrategic or Co-development PartnerFounding member of Australia's oldest and most established health innovation precinct. Located in the heart of Sydney, this partnership focuses on medical research and healthcare delivery collaboration.
• St Vincent's Sydney Public and Private HospitalscoreStrategic or Co-development PartnerCornerstone partner working collaboratively on medical research and healthcare delivery. Clinical collaboration enables translation of discoveries to patient care.
• Victor Chang Cardiac Research InstitutecoreStrategic or Co-development PartnerCornerstone partner in the St Vincent's Sydney Health Innovation Precinct, collaborating on cardiac research and broader medical innovation initiatives.
• UNSW SydneycoreStrategic or Co-development PartnerStrong ties to UNSW Sydney. Over 100 PhD, Masters, and Honours students are enrolled through UNSW and conduct research at Garvan under conjoint appointments. Students have access to both Garvan and UNSW resources.
• Australian BioResources (ABR)secondaryStrategic or Co-development PartnerJoint facility with Australian BioResources located on the same land as Garvan Institute. ABR provides animal research services supporting Garvan's in vivo disease research.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Centenary Institute: Sydney-based independent medical research institute focused on cancer, inflammation, and immunity research, with similar program structure and translational orientation; directly comparable Australian biomedical research peer.
• Hudson Institute of Medical Research: Melbourne-based medical research institute focused on cancer, infection, and women's and infant health with NHMRC-style funding; comparable in scope and Australian nonprofit research positioning.
• The Jackson Laboratory: US-based independent biomedical research institution focused on mammalian genetics, cancer, and immunology; functionally similar mission as a nonprofit research organization with strong commercialization pathways.
• St. Vincent's Institute of Medical Research: Melbourne-based medical research institute affiliated with St. Vincent's Hospital focused on cancer, diabetes, and immunology; shares Australian academic-hospital-affiliated research institute model with Garvan.
• Wellcome Sanger Institute: UK-based genomics and cellular-genetics research institute with strengths in cancer, immune, and infectious disease genomics; closely comparable on genomics orientation and population-scale cohort work to Garvan's OneK1K and TenK10K programs.
• The Francis Crick Institute: Major UK biomedical discovery institute conducting research across cancer, immunology, and genomics at scale; comparable in mission and program breadth, although larger and more internationally staffed.
• South Australian Health and Medical Research Institute (SAHMRI): Adelaide-based independent medical research institute with similar programs in cancer, nutrition, and Aboriginal health; comparable Australian nonprofit research positioning and translational orientation.
• Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's largest biomedical research institute, located in Melbourne, focused on cancer, immunology, and infectious disease; directly comparable in mission, scale, and funding model (NHMRC-funded independent medical research institute).
• Cold Spring Harbor Laboratory: Long-standing US private research and education institution in cancer, neuroscience, and quantitative biology; peer in independent nonprofit biomedical research with significant publication and training footprint.

Broad incumbents

• Broad Institute: MIT- and Harvard-affiliated genomics and biomedical research institute operating at significantly larger scale, with overlapping focus areas in cancer, genomic medicine, and single-cell biology; broader incumbent rather than direct head-to-head competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/garvaninstitute
• YouTubeyoutube.com/user/GarvanInstitute
• Facebookfacebook.com/garvaninstitute
• LinkedInlinkedin.com/company/garvan-institute-of-medical-rese
• Instagraminstagram.com/garvaninstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Garvan Institute of Medical Research